Bookbuilding IPO | ₹1,348 Cr | Listed at BSE, NSE | Tue, Dec 8, 2015 - Thu, Dec 10, 2015
Alkem Laboratories IPO is a book build issue of ₹1,347.76 crores. The issue is entirely an offer for sale of 1.29 crore shares of ₹1,347.76 crore.
Alkem Laboratories IPO bidding started from Dec 8, 2015 and ended on Dec 10, 2015. The shares got listed on BSE, NSE on Dec 23, 2015.
Alkem Laboratories IPO price band is set at ₹1,050 per share. The lot size for an application is 14. The minimum amount of investment required by an retail is ₹14,700 (14 shares) (based on upper price). The lot size investment for sNII is 14 lots (196 shares), amounting to ₹2,05,800, and for bNII, it is 69 lots (966 shares), amounting to ₹10,14,300.
The issue includes a reservation of up to 2,98,913 shares for employees offered at a discount of ₹100.00 to the issue price.
Axis Capital Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Alkem Laboratories IPO RHP for detailed Information.
IPO Open
Tue, Dec 8, 2015
IPO Close
Thu, Dec 10, 2015
Issue Price
₹1050 per share
Market Cap (Pre-IPO)
₹12,554.33 Cr
| IPO Date | 8 to 10 Dec, 2015 |
| Listed on | Wed, Dec 23, 2015 |
| Face Value | ₹2 per share |
| Price Band | ₹1020 to ₹1050 |
| Issue Price | ₹1050 per share |
| Lot Size | 14 Shares |
| Sale Type | OFS only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Employee Discount | ₹100.00 |
| Total Issue Size | 1,28,53,442 shares (agg. up to ₹1,348 Cr) |
| Offer for Sale | 1,28,53,442 shares of ₹2 (agg. up to ₹1,348 Cr) |
| Share Holding Pre Issue | 11,95,65,000 shares |
| Share Holding Post Issue | 11,95,65,000 shares |
| BSE Script Code / NSE Symbol | 539523 / ALKEM |
| ISIN | INE540L01014 |
Alkem Laboratories IPO comprises a total issue size of 1,28,53,442 shares. The net offer to the public is 1,25,54,529 shares, after excluding 2,98,913 shares under a preferential allotment. Of the Net offer 62,77,264 (50.00%) are allocated to QIB, 18,83,179 (15.00%) allocated to NII 43,94,086 (35.00%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue | Max Allottees |
|---|---|---|---|---|
| QIB Shares Offered | 62,77,264 | 50.00% | 48.84% | NA |
| − Anchor Investor Shares Offered | 37,66,358 | 29.30% | NA | |
| − QIB (Ex. Anchor) Shares Offered | 25,10,906 | 19.53% | NA | |
| NII (HNI) Shares Offered | 18,83,179 | 15.00% | 14.65% | NA |
| Retail Shares Offered | 43,94,086 | 35.00% | 34.19% | 3,13,863 |
| Preferential Reservations | ||||
| Employee Shares Offered | 2,98,913 | 2.33% | NA | |
| Total Shares Offered | 1,28,53,442 | 100.00% | 100.00% | |
Investors can bid for a minimum of 14 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,700 |
| Retail (Max) | 13 | 182 | ₹1,91,100 |
| S-HNI (Min) | 14 | 196 | ₹2,05,800 |
| S-HNI (Max) | 68 | 952 | ₹9,99,600 |
| B-HNI (Min) | 69 | 966 | ₹10,14,300 |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Yes | |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Incorporated in 1973, Alkem Labs is leading India based pharmaceutical company engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products.
Alkem Labs produces branded generics, generic drugs, active pharmaceutical ingredients and neutraceuticals, which they market in India and 55 countries internationally, primarily the United States.
Company's pharmaceutical business is organized into domestic and international operations. Alkem Labs has a portfolio of over 736 brands in India. Company's most significant therapeutic areas in domestic market are anti-infectives, gastro-intestinal, pain and analgesics, and vitamins, minerals and nutrients.
Alkem Labs have a total of 16 manufacturing facilities: 14 manufacturing facilities at five locations in India and two in the United States. Company have four research and development facilities, two in India and two in the United States. As of June 30, 2015, company employed 483 scientists in research and development functions.
Highlights:
1. Alkem Labs is 5th largest pharmaceutical company in India in terms of domestic sales.
2. Alkem Labs products are also sold in 56 countries. In the United States, company has filed 66 abbreviated new drug applications.
3. Company sells a range of high-quality, cost effective generic drugs to major drug chains, pharmaceutical retailers, wholesalers, food and grocery stores, distributors and managed care companies in the United States.
| Period Ended |
|---|
| Amount in ₹ Crore |
| KPI | |
|---|---|
| RoNW | 15.4% |
| Pre IPO | Post IPO | |
|---|---|---|
| Promoter Holding | 70.87% | 66.23% |
| Market Cap | ₹12,554.33 Cr. |
The Alkem Laboratories IPO is subscribed 44.29 times on December 10, 2015 11:15:00 PM (Day 3). The public issue subscribed 3.17 times in the retail category, 57.19 times in the QIB category, and 129.96 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB | 57.19 | 25,10,906 | |
| NII | 129.96 | 18,83,179 | |
| Retail | 3.17 | 43,94,086 | |
| Employee | 0.67 | 2,98,913 | |
| Total | 44.29 | 90,87,084 |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | GCBRLMs’ fees and commission (including underwriting commission, brokerage and selling commission) | 442.15 |
| 2 | Commission / processing fee for SCSBs and Bankers to the Issue and brokerage and selling commission for Registered Brokers | 2.00 |
| 3 | Registrar to the Issue | 0.80 |
| 4 | Other advisors to the Issue | 106.17 |
| 5 | Listing fees, SEBI filing fees, book building software fees, STT | 55.19 |
| 6 | Printing and stationary | 27.00 |
| 7 | Advertising and marketing expenses | 55.54 |
| 8 | Miscellaneous | 72.52 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹1,050.00 | ₹1,050.00 |
| Open | ₹1,380.00 | ₹1,380.00 |
| Low | ₹1,355.40 | ₹1,356.20 |
| High | ₹1,410.00 | ₹1,413.70 |
| Last Trade | ₹1,381.45 | ₹1,381.70 |
Alkem Laboratories IPO is a main-board IPO of 1,28,53,442 equity shares of the face value of ₹2 aggregating up to ₹1,348 Crores. The issue is priced at ₹1050 per share. The minimum order quantity is 14.
The IPO opens on Tue, Dec 8, 2015, and closes on Thu, Dec 10, 2015.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Alkem Laboratories IPO using UPI as a payment gateway. Zerodha customers can apply in Alkem Laboratories IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Alkem Laboratories IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Alkem Laboratories IPO opens on Tue, Dec 8, 2015 and closes on Thu, Dec 10, 2015.
Alkem Laboratories IPO lot size is 14, and the minimum amount required for application is ₹14,700.
You can apply in Alkem Laboratories IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Alkem Laboratories IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Alkem Laboratories IPO allotment status.
The Alkem Laboratories IPO listing date is on Wed, Dec 23, 2015.
